Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328337 | 0.84 | ALDH1A1 (0.68) | POLBCHRM1MAPTALDH1A1KDM4E | |
| SCHEMBL11450998 | 0.82 | SMN1; SMN2 (0.68) | POLBMAPTALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL7854448 | 0.79 | POLB (0.92) | POLBCHRM1DDAH1NPC1RAB9A | |
| SCHEMBL7006523 | 0.79 | POLB (1.00) | POLBCHRM1DDAH1NPC1RAB9A | |
| SCHEMBL20561440 | 0.78 | MAPT (0.75) | POLBCHRM1MAPTALDH1A1KDM4E | |
| SCHEMBL7856315 | 0.78 | POLB (0.96) | POLBCHRM1MAPTKDM4EDDAH1 | |
| SCHEMBL30701864 | 0.78 | POLB (0.96) | POLBCHRM1MAPTKDM4EDDAH1 | |
| SCHEMBL7854826 | 0.78 | POLB (0.96) | POLBCHRM1MAPTKDM4EDDAH1 | |
| SCHEMBL7856311 | 0.78 | POLB (0.96) | POLBCHRM1MAPTKDM4EDDAH1 | |
| SCHEMBL30701863 | 0.78 | POLB (0.96) | POLBCHRM1MAPTKDM4EDDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED | 2007-11-29 | — | — | US | disclosed |
| US-7268145-B2 | Thiobenzimidazole derivatives | TEIJIN PHARMA LIMITED (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20060040976-A1 | Thiobenzimidazole derivatives | TEIJIN LIMITED | 2006-02-23 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| EP-1097926-A1 | THIOBENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2001-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275995-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | POLB 2181/4885CHRM1 4603/4885MAPT 4292/4885 |
| US-20060040976-A1 | Thiobenzimidazole derivatives | CMA1, SERPINB1, TMPRSS15 | POLB 2181/4885CHRM1 4603/4885MAPT 4292/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | POLB 2302/4885CHRM1 4587/4885MAPT 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.